Clinical trial
A Placebo-Controlled Multi-Center Phase IIa Dose Finding Study of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Patients With Relapsing Forms of Multiple Sclerosis.
NCT02738775 is registered in ClinicalTrials.gov with TG Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Placebo-Controlled Multi-Center Phase IIa Dose Finding Study of Ublituximab, a Third-Generation Anti-CD20 Monoclonal Antibody, in Patients With Relapsing Forms of Multiple Sclerosis.
- Lead sponsor
- TG Therapeutics, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- May 27, 2016
- Completion date
- August 13, 2018
- Enrollment
- 49 (actual)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.